Skip to main content

Table 1 Baseline characteristics of patients (n = 10)

From: The dipeptidyl peptidase-4 inhibitor may improve the insulin secretion in type 2 diabetes patients just after starting hemodialysis treatment: preliminary study

Characteristics Values
Age (years; mean ± SD) 54.2 ± 10.2
Gender (male/female) 7/3
BMI (mean ± SD) 23.7 ± 5.1
BP (mmHg/mean ± SD) 158 ± 21/85 ± 14
Diabetic duration (years; mean ± SD) 11.2 ± 7.9
Admission reason HD initiation (all 10 patients)
Hb (g/dL) 8.5 ± 1.9
Alb (g/dL) 2.7 ± 0.38
HbA1c (%; mean ± SD) 5.7 ± 0.6
Glycated albumin (GA) (%; mean ± SD) 17.4 ± 3.5
Fasting plasma glucose (mg/dl; mean ± SD) 117 ± 22
Postprandial plasma glucose 172 ± 20
Pre-HD plasma glucose 184 ± 14
Previous anti-diabetic agent (−): 7, alpha GI: 1, αGI + mitiglinide: 1, insulin:1
Dialysate Kindary 2E (glucose: 100 mg/dl)
Dialyser Polysulfone (PS): 8, cellulose triacetate(CTA): 2
HD time 3 h
Quantity of blood (QB: ml/m) 146 ± 11
Quantity of dialysate (QD: ml/m) 500
KT/V 0.73 ± 0.24
Vitamin D treatment (+):3, (−):7
Residual kidney function Urine volume 888 ± 461 (pre)→519 ± 185 (post)
Glycosuria (±):2 (+):5 (2+):3